Bristol-Myers Squibb Co vs EHang Holdings Ltd - ADR — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while EHang Holdings Ltd - ADR trades at $5.85 (market cap $437.63M). The key difference: Bristol-Myers Squibb Co is far larger — about 296.9× EHang Holdings Ltd - ADR's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.
| BMY | EH | |
|---|---|---|
Market Cap | $129.94B | $437.63M |
Sector | Health | Industrials |
52-Week High | $65.89 | $19.44 |
52-Week Low | $42.60 | $4.90 |
Enterprise Value | $163.92B | $376.84M |
Dividend Yield | 3.96% | — |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →